LQDA, US53635D2027

Liquidia stock gets HC Wainwright Buy rating

Published on 11/13/2026 at 22:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

HC Wainwright launched coverage with a Buy rating. Liquidia stock traded at 52.07 euros on Lang & Schwarz at 22:00 CET Friday.

Key takeaways for investors

HC Wainwright started coverage on November 13 with a Buy rating and a USD 76 price target.
MarketBeat reported an average analyst rating of Hold and a consensus price target of USD 75.23.
Liquidia's third-quarter revenue reached USD 225.30 million, while a one-time settlement charge drove a USD 236.3 million net loss.

LQDA, US53635D2027, Illustration mit AI erstellt.

HC Wainwright initiated coverage of Liquidia on Friday, November 13, assigning the biopharmaceutical company a Buy rating and a USD 76 price target, according to MarketBeat.

The target was announced after Liquidia's third-quarter results on November 10. MarketBeat cited an average analyst rating of Hold and a consensus price target of USD 75.23, with twelve analysts covering the company.

Operating backdrop after Q3

Liquidia reported third-quarter revenue of USD 225.30 million, above the USD 214.18 million analyst estimate cited by MarketBeat. YUTREPIA net product sales reached USD 222.7 million, up 31% from the second quarter, while adjusted EBITDA rose to USD 140.5 million for a fifth consecutive quarter.

The company nevertheless posted a USD 236.3 million net loss. A one-time USD 389.7 million litigation settlement charge related to the agreement with United Therapeutics drove the reported loss and remains central to the earnings picture.

Liquidia stock traded at 52.07 euros on Lang & Schwarz at 22:00 CET on Friday, November 13.